Accueil   Diary - News   All news IXALTIS announces successful completion of phase 2 for its compound Litoxtine

IXALTIS announces successful completion of phase 2 for its compound Litoxtine

 

 

Toulouse (31) /Archamps (74), May, 14th, 2019 – Ixaltis is pleased to announce successful completion of the phase 2 of clinical development in urinary incontinence for its lead compound Litoxetine. Litoxetine is an SSRI (Selective Serotonin Reuptake Inhibitor) and serotonin agonist-antagonist with specific activities on some receptor subtypes. The positivie results pave the way to progress to phase 3 for this compound with the potential of being "first in class" for treating mixed urinary incontinence, a disease for which there is no appoved medical treatment on the market.

 

Read the press release

By continuing to browse our site you agree to our use of cookies, revised Privacy Policy and Terms of Service. More information... Close